NCT00366431View on ClinicalTrials.gov

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

August 31, 2006

Study Completion Date

March 31, 2007

Conditions
Constipation
Interventions
DRUG

MOA-728

Trial Locations (67)

11023

Great Neck

11042

Lake Success

21075

Elkridge

22304

Alexandria

23229

Richmond

23502

Norfolk

24073

Christiansburg

27103

Winston-Salem

28210

Charlotte

30060

Marietta

30066

Marietta

30534

Dawsonville

32174

Ormond Beach

32216

Jacksonville

33021

Hollywood

33173

Miami

33180

Miami

33401

West Palm Beach

33458

Jupiter

33607

Tampa

33770

Largo

34471

Ocala

34769

Saint Cloud

35215

Birmingham

35244

Birmingham

36608

Mobile

37404

Chattanooga

39466

Picayune

45219

Cincinnati

45224

Cincinnati

45439

Dayton

46250

Indianapolis

48602

Saginaw

49684

Traverse City

59808

Missoula

60610

Chicago

61701

Bloomington

64055

Independence

68114

Omaha

71913

Hot Springs

73601

Clinton

76034

Colleyville

77701

Beaumont

78205

San Antonio

78209

San Antonio

78238

San Antonio

85029

Phoenix

85710

Tucson

85712

Tucson

85741

Tucson

87102

Albuquerque

89502

Reno

92108

San Diego

92120

San Diego

92121

San Diego

92610

Foothill Ranch

92801

Anaheim

92805

Anaheim

92843

Garden Grove

92869

Orange

93311

Bakersfield

95032

Los Gatos

95831

Sacramento

06611

Trumbull

02115

Boston

02301

Brockton

08035

Haddon Heights

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00366431 - Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain | Biotech Hunter | Biotech Hunter